Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.6736
-0.0274 (-3.91%)
May 12, 2025, 3:53 PM - Market open
Lexicon Pharmaceuticals Revenue
In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth. Lexicon Pharmaceuticals had revenue of $26.55M in the quarter ending December 31, 2024, with 3,682.62% growth.
Revenue (ttm)
$31.08M
Revenue Growth
+2,481.48%
P/S Ratio
7.22
Revenue / Employee
$301,757
Employees
103
Market Cap
243.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LXRX News
- 5 days ago - Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 6 days ago - Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewsWire
- 17 days ago - Top 2 Health Care Stocks That May Crash This Month - Benzinga
- 5 weeks ago - Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal - Market Watch
- 6 weeks ago - Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
- 6 weeks ago - Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 - GlobeNewsWire
- 2 months ago - Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire